Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy

AIDS

Volumn 27, Issue 2, 2013, Pages 203-210

  Du Pasquier, Renaud A ^a   Jilek, Samantha ^a   Kalubi, Malela ^a   Yerly, Sabine ^b   Fux, Christoph A ^c   Gutmann, Christine ^d   Cusini, Alexia ^c,e   Günthard, Huldrych F ^e   Cavassini, Matthias ^a   Vernazza, Pietro L ^d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

astrocyte; central nervous system; HIV; lopinavir ritonavir; monotherapy; neopterin; S100B

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEOPTERIN; PROTEIN S100B; RITONAVIR; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; ASTROCYTOSIS; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; PRIORITY JOURNAL; VIRUS LOAD;

AMYLOID BETA-PEPTIDES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASTROCYTES; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LOPINAVIR; NEOPTERIN; PEPTIDE FRAGMENTS; RITONAVIR; S100 PROTEINS; SWITZERLAND; TAU PROTEINS; THAILAND;

EID: 84872417107     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835a9a4a     Document Type: Article

References (33)

1. Valcour V, Sithinamsuwan P, Letendre S, Ances B. Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep 2011; 8:54-61.
2. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol 2005; 4:543-555.
3. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neuro-cognitive disorders. Neurology 2007; 69:1789-1799.
4. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24:1243-1250.
5. Vance DE, McGuinness T, Musgrove K, Orel NA, Fazeli PL. Successful aging and the epidemiology of HIV. Clin Interv Aging 2011; 6:181-192.
6. Brew BJ, Crowe SM, Landay A, Cysique LA, Guillemin G. Neurodegeneration and ageing in the HAART era. J. Neuro-immune Pharmacol 2009; 4:163-174.
7. Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, Evans S, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 2010; 74:1260-1266.
8. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol 2005; 5:69-81.
9. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
10. Gutmann C, Cusini A, Günthard H, Fux C, Hirschel B, Decosterd L, et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 2010; 24:2347-2354.
11. Vernazza P, Daneel S, Schiffer V, Decosterd L, Fierz W, Klimkait T, et al. The role of compartment penetration in PI-monother-apy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 2007; 21:1309-1315.
12. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6:131-144.
13. Clifford D, Fagan A, Holtzman D, Morris JC, Teshome M, Shah AR, et al. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology 2009; 73:1982-1987.
14. Brew BJ, Letendre SL. Biomarkers of HIV related central nervous system disease. Int Rev Psy 2008; 20:73-88.
15. Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich S, Bestetti A, et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 2010; 7:15.
16. Hu J, Ferreira A, Van Eldik LJ. S100beta induces neuronal cell death through nitric oxide release from astrocytes. J Neuro-chem 1997; 69:2294-2301.
17. Reali C, Pillai R, Saba F, Cabras S, Michetti F, Sogos V. S100B modulates growth factors and costimulatory molecules expression in cultured human astrocytes. J Neuroimmunol 2012; 243:95-99.
18. Swiss HIVCS, Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Gunthard HF, et al. Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol 2010; 39:1179-1189.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944.
20. Spies PE, Slats D, Sjogren JM, Kremer BP, Verhey FR, Rikkert MG, et al. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Curr Alzheimer Res 2010; 7:470-476.
21. Takahashi K, Wesselingh SL, Griffin DE, McArthur JC, Johnson RT, Glass JD. Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immuno-cytochemistry. Ann Neurol 1996; 39:705-711.
22. Churchill M, Wesselingh S, Cowley D, Pardo C, McArthur J, Brew B, et al. Extensive astrocyte infection is prominent in human immunodeficiency virus-associated dementia. Ann Neurol 2009; 66:253-258.
23. Eugenin EA, Clements JE, Zink MC, Berman JW. Human immunodeficiency virus infection of human astrocytes disrupts blood-brain barrier integrity by a gap junction-dependent mechanism. J Neurosci 2011; 31:9456-9465.
24. Pemberton LA, Brew BJ. Cerebrospinal fluid S-100beta and its relationship with AIDS dementia complex. J Clin Virol 2001; 22:249-253.
25. Renner NA, Redmann RK, Moroney-Rasmussen T, Sansing HA, Aye PP, Didier PJ, et al. S100beta as a novel and accessible indicator for the presence of monocyte-driven encephalitis in AIDS. Neuropathol Appl Neurobiol 2012; 38:162-174.
26. Woods SP, Iudicello JE, Dawson MS, Weber E, Grant I, Letendre SL. HIV-associated deficits in action (verb) generation may reflect astrocytosis. J Clin Exp Neuropsychol 2010; 32:522-527.
27. Griffin DE, McArthur JC, Cornblath DR. Neopterin and inter-feron-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology 1991; 41:69-74.
28. Yilmaz A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslen M. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 47:168-173.
29. Brew BJ, Pemberton L, Blennow K, Wallin A, Hagberg L. CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology 2005; 65:1490-1492.
30. Gisslen M, Krut J, Andreasson U, et al. Amyloid and tau cerebro-spinal fluid biomarkers in HIV infection. BMC Neurol 2009; 9.
31. Rempel HC, Pulliam L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 2005; 19:127-135.
32. McArthur JC, McClernon DR, Cronin MF, Nance-Sproson TE, Saah AJ, St Clair M, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997; 42:689-698.
33. Zink MC, Brice AK, Kelly KM, Queen SE, Gama L, Li M, et al. Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis 2010; 202:161-170.